Inhibition of CP with an anti-C1s mAb (Sutimlimab) abrogated extravascular hemolysis in CAD patients supporting an important role of complement as a pathogenic factor in CAD and the CP as a therapeutic target (29). This evidence concerns the gene C1S and cold agglutinin disease.